Pharmafile Logo
Pharmafocus logo
Advanced Search

Novo Nordisk

Showing 15 posts of 177 posts found.

Novo Nordisk delivers in much-anticipated oral semaglutide diabetes trial

February 23, 2018
Medical Communications, Research and Development Novo Nordisk, diabetes, pharma, semaglutide, type 2 diabetes

Novo Nordisk has lifted the curtain on much-anticipated results data from the first of ten Phase 3 trials into the …

News

Novo’s Ozempic secures European approval in type 2 diabetes

February 12, 2018
Sales and Marketing EC, EMA, Europe, Novo Nordisk, diabetes, pharma

Novo Nordisk has revealed that its drug Ozempic (semaglutide) has received approval from the European Commission (EC) as a monotherapy …

News
ablynx_flags-web

Novo Nordisk ups acquisition bid to €2.6 billion, Ablynx says no

January 8, 2018
Sales and Marketing Ablynx, Novo Nordisk, acquisition, pharma

It has emerged that Novo Nordisk has extended a bid of €2.6 billion to buy Belgian biotech Ablynx. The new …

News
novo_flag

Novo Nordisk unveils hard-hitting data for two of its diabetes therapies

December 5, 2017
Manufacturing and Production, Research and Development Novo Nordisk, Tresiba, Xultophy, diabetes, pharma

Novo Nordisk has lifted the curtain on new data from two of its therapies for diabetes, Xultophy (insulin degludec/liraglutide) and …

News

Novo’s diabetes treatment semaglutide gets unanimous FDA backing

October 19, 2017
Sales and Marketing Novo Nordisk, diabetes, semaglutide

Novo Nordisk is celebrating the news that its diabetes drug semaglutide has won the favour of FDA experts, with one …

News
hassan_fahmi

Novo Nordisk Egypt promotes new General Manager

September 28, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Novo Nordisk, biotech, drugs, pharma, pharmaceutical

Novo Nordisk Egypt has promoted Hassan Fahmi to become its new General Manager for operations within the company. Fahmi arrived …

Appointment

Novo’s Xultophy beats basal insulin in cutting cardiovascular risk

September 14, 2017
Research and Development Novo Nordisk, Xultophy, diabetes, pharma, pharmaceutical, type 2 diabetes

Novo Nordisk has unveiled new data on its diabetes treatment Xultophy (insulin degludec/liraglutide) which supports its efficacy in reducing risk …

News
novo_flag

Novo Nordisk settles lawsuit over illegal marketing practices for $58.7 million

September 6, 2017
Research and Development, Sales and Marketing FDA, Novo Nordisk, US, US Justice Department, Victoza, diabetes, pharma, pharmaceutical

Novo Nordisk has resolved a probe by the US Justice Department which accused the Danish drugmaker of illegal marketing activities …

News
novo_flag

Novo diabetes drug outperforms Lilly rival at Phase 3

August 17, 2017
Research and Development Eli Lilly, Novo Nordisk, diabetes, life sciences, medicine, pharma, pharmaceutical, type 2 diabetes

Novo Nordisk has revealed that its diabetes drug semaglutide managed to outperform Eli Lilly’s own treatment dulaglutide (Trulicity) in controlling …

News
doug_langa

Novo Nordisk reshuffles Executive Management team with two major additions

August 15, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Novo Nordisk, appointment, life sciences, medicine, pharma, pharmaceutical

This month has seen two new additions to Novo Nordisk’s Executive Management team. First of the pair is Camila Sylvest, …

Appointment
hoiland

Radius bolsters leadership with appointment of Novo Vet

July 18, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Novo Nordisk, Radius, biotech, drugs, pharma, pharmaceutical

Jesper Høiland has been revealed as the new President and Chief Executive Officer of Radius. The news comes shortly after …

Appointment

Novo Nordisk’s diabetes drug recommended for expanded indication in Europe

June 27, 2017
Research and Development, Sales and Marketing CHMP, EMA, EU, Novo Nordisk, Victoza

The EMA’s Committee for Medicinal Products for Human Use (CHMP) has given its recommendation to expand the indication of Novo …

News
novo_nordisk_flag

Promising Phase 2 obesity data for Novo’s diabetes drug

June 26, 2017
Research and Development, Sales and Marketing Novo Nordisk

Novo Nordisk is hopeful about the prospects of its diabetes drug semaglutide as a treatment for obesity after it produced …

News
novo_nordisk_flag

FDA backs Novo’s diabetes drug for cardiovascular efficacy

June 21, 2017
Research and Development Novo Nordisk, Victoza

Good news for Novo Nordisk as the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the FDA recommends that data …

News

Novo Nordisk eyes acquisition of Global Blood Therapeutics

March 9, 2017
Sales and Marketing Global Blood Therapeutics, Novo Nordisk

Novo Nordisk has been notoriously shy when it comes to making acquisitions but Reuters has reported that this may be …

News

Latest content

Regeneron shares data for multiple myeloma treatment

December 8, 2023

Merck collaborates with Acceleration Consortium for AI experimentation

December 8, 2023

AbbVie to acquire Cerevel Therapeutics for approximately $8.7bn

December 7, 2023

ONK Therapeutics and NAYA Biosciences enter partnership for NK cell therapy development

December 7, 2023

FDA approves Novartis’ Fabhalta for PNH treatment

December 6, 2023